Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
27,461
archived clinical trials in
Hematology

Cervical Spondylotic Myelopathy Surgical Trial
Cervical Spondylotic Myelopathy Surgical Trial
Status: Enrolling
Updated:  3/30/2018
University of Wisconsin
mi
from
Madison, WI
Cervical Spondylotic Myelopathy Surgical Trial
Cervical Spondylotic Myelopathy Surgical Trial
Status: Enrolling
Updated: 3/30/2018
University of Wisconsin
mi
from
Madison, WI
Click here to add this to my saved trials
Cervical Spondylotic Myelopathy Surgical Trial
Cervical Spondylotic Myelopathy Surgical Trial
Status: Enrolling
Updated:  3/30/2018
Medical College of Wisconsin
mi
from
Milwaukee, WI
Cervical Spondylotic Myelopathy Surgical Trial
Cervical Spondylotic Myelopathy Surgical Trial
Status: Enrolling
Updated: 3/30/2018
Medical College of Wisconsin
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Cervical Spondylotic Myelopathy Surgical Trial
Cervical Spondylotic Myelopathy Surgical Trial
Status: Enrolling
Updated:  3/30/2018
University Health Network-University of Toronto
mi
from
Toronto,
Cervical Spondylotic Myelopathy Surgical Trial
Cervical Spondylotic Myelopathy Surgical Trial
Status: Enrolling
Updated: 3/30/2018
University Health Network-University of Toronto
mi
from
Toronto,
Click here to add this to my saved trials
Cervical Spondylotic Myelopathy Surgical Trial
Cervical Spondylotic Myelopathy Surgical Trial
Status: Enrolling
Updated:  3/30/2018
University of Pittsburgh Medical Center
mi
from
Pittsburgh, PA
Cervical Spondylotic Myelopathy Surgical Trial
Cervical Spondylotic Myelopathy Surgical Trial
Status: Enrolling
Updated: 3/30/2018
University of Pittsburgh Medical Center
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Cervical Spondylotic Myelopathy Surgical Trial
Cervical Spondylotic Myelopathy Surgical Trial
Status: Enrolling
Updated:  3/30/2018
Washington University School of Medicine St. Louis
mi
from
Saint Louis, MO
Cervical Spondylotic Myelopathy Surgical Trial
Cervical Spondylotic Myelopathy Surgical Trial
Status: Enrolling
Updated: 3/30/2018
Washington University School of Medicine St. Louis
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Patients
Phase II Trial of Low Toxicity GVHD Prevention and Enhanced Immune Recovery With Tacrolimus, Bortezomib and Thymoglobulin® TBT
Status: Enrolling
Updated:  3/30/2018
Emory University/Winship Cancer Institute
mi
from
Atlanta, GA
Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Patients
Phase II Trial of Low Toxicity GVHD Prevention and Enhanced Immune Recovery With Tacrolimus, Bortezomib and Thymoglobulin® TBT
Status: Enrolling
Updated: 3/30/2018
Emory University/Winship Cancer Institute
mi
from
Atlanta, GA
Click here to add this to my saved trials
Selinexor and Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Phase 1 Study of Selinexor in Combination With Topoisomerase-II Inhibition in Acute Myeloid Leukemia
Status: Enrolling
Updated:  4/2/2018
The Ohio State University Comprehensive Cancer Center
mi
from
Columbus, OH
Selinexor and Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Phase 1 Study of Selinexor in Combination With Topoisomerase-II Inhibition in Acute Myeloid Leukemia
Status: Enrolling
Updated: 4/2/2018
The Ohio State University Comprehensive Cancer Center
mi
from
Columbus, OH
Click here to add this to my saved trials
Prognostic Potential of Cell Surface Markers and Pim Kinases in Multiple Myeloma
Prognostic Potential of Cell Surface Markers and Pim Kinases in Multiple Myeloma
Status: Enrolling
Updated:  4/3/2018
Medical University of South Carolina
mi
from
Charleston, SC
Prognostic Potential of Cell Surface Markers and Pim Kinases in Multiple Myeloma
Prognostic Potential of Cell Surface Markers and Pim Kinases in Multiple Myeloma
Status: Enrolling
Updated: 4/3/2018
Medical University of South Carolina
mi
from
Charleston, SC
Click here to add this to my saved trials
Phase II Part 2 Expansion of Oral Rigosertib in Combination With Azacitidine
A Phase I/II, Multi-center, Dose-escalating Study of the Tolerability, Pharmacokinetics, and Clinical Activity of the Combined Administration of Oral Rigosertib With Azacitidine in Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia
Status: Enrolling
Updated:  4/3/2018
Mount Sinai Hospital
mi
from
New York, NY
Phase II Part 2 Expansion of Oral Rigosertib in Combination With Azacitidine
A Phase I/II, Multi-center, Dose-escalating Study of the Tolerability, Pharmacokinetics, and Clinical Activity of the Combined Administration of Oral Rigosertib With Azacitidine in Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia
Status: Enrolling
Updated: 4/3/2018
Mount Sinai Hospital
mi
from
New York, NY
Click here to add this to my saved trials
Phase II Part 2 Expansion of Oral Rigosertib in Combination With Azacitidine
A Phase I/II, Multi-center, Dose-escalating Study of the Tolerability, Pharmacokinetics, and Clinical Activity of the Combined Administration of Oral Rigosertib With Azacitidine in Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia
Status: Enrolling
Updated:  4/3/2018
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Phase II Part 2 Expansion of Oral Rigosertib in Combination With Azacitidine
A Phase I/II, Multi-center, Dose-escalating Study of the Tolerability, Pharmacokinetics, and Clinical Activity of the Combined Administration of Oral Rigosertib With Azacitidine in Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia
Status: Enrolling
Updated: 4/3/2018
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Phase II Part 2 Expansion of Oral Rigosertib in Combination With Azacitidine
A Phase I/II, Multi-center, Dose-escalating Study of the Tolerability, Pharmacokinetics, and Clinical Activity of the Combined Administration of Oral Rigosertib With Azacitidine in Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia
Status: Enrolling
Updated:  4/3/2018
Hôpital St. Louis
mi
from
Paris,
Phase II Part 2 Expansion of Oral Rigosertib in Combination With Azacitidine
A Phase I/II, Multi-center, Dose-escalating Study of the Tolerability, Pharmacokinetics, and Clinical Activity of the Combined Administration of Oral Rigosertib With Azacitidine in Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia
Status: Enrolling
Updated: 4/3/2018
Hôpital St. Louis
mi
from
Paris,
Click here to add this to my saved trials
Phase II Part 2 Expansion of Oral Rigosertib in Combination With Azacitidine
A Phase I/II, Multi-center, Dose-escalating Study of the Tolerability, Pharmacokinetics, and Clinical Activity of the Combined Administration of Oral Rigosertib With Azacitidine in Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia
Status: Enrolling
Updated:  4/3/2018
White Plains Hospital Center for Cancer Care
mi
from
White Plains, NY
Phase II Part 2 Expansion of Oral Rigosertib in Combination With Azacitidine
A Phase I/II, Multi-center, Dose-escalating Study of the Tolerability, Pharmacokinetics, and Clinical Activity of the Combined Administration of Oral Rigosertib With Azacitidine in Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia
Status: Enrolling
Updated: 4/3/2018
White Plains Hospital Center for Cancer Care
mi
from
White Plains, NY
Click here to add this to my saved trials
Phase II Part 2 Expansion of Oral Rigosertib in Combination With Azacitidine
A Phase I/II, Multi-center, Dose-escalating Study of the Tolerability, Pharmacokinetics, and Clinical Activity of the Combined Administration of Oral Rigosertib With Azacitidine in Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia
Status: Enrolling
Updated:  4/3/2018
Saint Louis University
mi
from
Saint Louis, MO
Phase II Part 2 Expansion of Oral Rigosertib in Combination With Azacitidine
A Phase I/II, Multi-center, Dose-escalating Study of the Tolerability, Pharmacokinetics, and Clinical Activity of the Combined Administration of Oral Rigosertib With Azacitidine in Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia
Status: Enrolling
Updated: 4/3/2018
Saint Louis University
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Phase II Part 2 Expansion of Oral Rigosertib in Combination With Azacitidine
A Phase I/II, Multi-center, Dose-escalating Study of the Tolerability, Pharmacokinetics, and Clinical Activity of the Combined Administration of Oral Rigosertib With Azacitidine in Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia
Status: Enrolling
Updated:  4/3/2018
City of Hope
mi
from
Duarte, CA
Phase II Part 2 Expansion of Oral Rigosertib in Combination With Azacitidine
A Phase I/II, Multi-center, Dose-escalating Study of the Tolerability, Pharmacokinetics, and Clinical Activity of the Combined Administration of Oral Rigosertib With Azacitidine in Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia
Status: Enrolling
Updated: 4/3/2018
City of Hope
mi
from
Duarte, CA
Click here to add this to my saved trials
Phase II Part 2 Expansion of Oral Rigosertib in Combination With Azacitidine
A Phase I/II, Multi-center, Dose-escalating Study of the Tolerability, Pharmacokinetics, and Clinical Activity of the Combined Administration of Oral Rigosertib With Azacitidine in Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia
Status: Enrolling
Updated:  4/3/2018
Carolina Blood and Cancer Care Associates PA
mi
from
Rock Hill, SC
Phase II Part 2 Expansion of Oral Rigosertib in Combination With Azacitidine
A Phase I/II, Multi-center, Dose-escalating Study of the Tolerability, Pharmacokinetics, and Clinical Activity of the Combined Administration of Oral Rigosertib With Azacitidine in Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia
Status: Enrolling
Updated: 4/3/2018
Carolina Blood and Cancer Care Associates PA
mi
from
Rock Hill, SC
Click here to add this to my saved trials
Phase II Part 2 Expansion of Oral Rigosertib in Combination With Azacitidine
A Phase I/II, Multi-center, Dose-escalating Study of the Tolerability, Pharmacokinetics, and Clinical Activity of the Combined Administration of Oral Rigosertib With Azacitidine in Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia
Status: Enrolling
Updated:  4/3/2018
Rush University Medical Center
mi
from
Chicago, IL
Phase II Part 2 Expansion of Oral Rigosertib in Combination With Azacitidine
A Phase I/II, Multi-center, Dose-escalating Study of the Tolerability, Pharmacokinetics, and Clinical Activity of the Combined Administration of Oral Rigosertib With Azacitidine in Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia
Status: Enrolling
Updated: 4/3/2018
Rush University Medical Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Phase II Part 2 Expansion of Oral Rigosertib in Combination With Azacitidine
A Phase I/II, Multi-center, Dose-escalating Study of the Tolerability, Pharmacokinetics, and Clinical Activity of the Combined Administration of Oral Rigosertib With Azacitidine in Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia
Status: Enrolling
Updated:  4/3/2018
Froedtert Hospital, Medical College of Wisconsin
mi
from
Milwaukee, WI
Phase II Part 2 Expansion of Oral Rigosertib in Combination With Azacitidine
A Phase I/II, Multi-center, Dose-escalating Study of the Tolerability, Pharmacokinetics, and Clinical Activity of the Combined Administration of Oral Rigosertib With Azacitidine in Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia
Status: Enrolling
Updated: 4/3/2018
Froedtert Hospital, Medical College of Wisconsin
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Phase II Part 2 Expansion of Oral Rigosertib in Combination With Azacitidine
A Phase I/II, Multi-center, Dose-escalating Study of the Tolerability, Pharmacokinetics, and Clinical Activity of the Combined Administration of Oral Rigosertib With Azacitidine in Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia
Status: Enrolling
Updated:  4/3/2018
Desert Hematology Oncology Medical Group, Inc
mi
from
Rancho Mirage, CA
Phase II Part 2 Expansion of Oral Rigosertib in Combination With Azacitidine
A Phase I/II, Multi-center, Dose-escalating Study of the Tolerability, Pharmacokinetics, and Clinical Activity of the Combined Administration of Oral Rigosertib With Azacitidine in Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia
Status: Enrolling
Updated: 4/3/2018
Desert Hematology Oncology Medical Group, Inc
mi
from
Rancho Mirage, CA
Click here to add this to my saved trials
Phase II Part 2 Expansion of Oral Rigosertib in Combination With Azacitidine
A Phase I/II, Multi-center, Dose-escalating Study of the Tolerability, Pharmacokinetics, and Clinical Activity of the Combined Administration of Oral Rigosertib With Azacitidine in Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia
Status: Enrolling
Updated:  4/3/2018
Cancer Center of Kansas
mi
from
Wichita, KA
Phase II Part 2 Expansion of Oral Rigosertib in Combination With Azacitidine
A Phase I/II, Multi-center, Dose-escalating Study of the Tolerability, Pharmacokinetics, and Clinical Activity of the Combined Administration of Oral Rigosertib With Azacitidine in Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia
Status: Enrolling
Updated: 4/3/2018
Cancer Center of Kansas
mi
from
Wichita, KA
Click here to add this to my saved trials
Phase II Part 2 Expansion of Oral Rigosertib in Combination With Azacitidine
A Phase I/II, Multi-center, Dose-escalating Study of the Tolerability, Pharmacokinetics, and Clinical Activity of the Combined Administration of Oral Rigosertib With Azacitidine in Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia
Status: Enrolling
Updated:  4/3/2018
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Phase II Part 2 Expansion of Oral Rigosertib in Combination With Azacitidine
A Phase I/II, Multi-center, Dose-escalating Study of the Tolerability, Pharmacokinetics, and Clinical Activity of the Combined Administration of Oral Rigosertib With Azacitidine in Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia
Status: Enrolling
Updated: 4/3/2018
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Click here to add this to my saved trials
Phase II Part 2 Expansion of Oral Rigosertib in Combination With Azacitidine
A Phase I/II, Multi-center, Dose-escalating Study of the Tolerability, Pharmacokinetics, and Clinical Activity of the Combined Administration of Oral Rigosertib With Azacitidine in Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia
Status: Enrolling
Updated:  4/3/2018
Banner MD Anderson Cancer Center
mi
from
Gilbert, AZ
Phase II Part 2 Expansion of Oral Rigosertib in Combination With Azacitidine
A Phase I/II, Multi-center, Dose-escalating Study of the Tolerability, Pharmacokinetics, and Clinical Activity of the Combined Administration of Oral Rigosertib With Azacitidine in Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia
Status: Enrolling
Updated: 4/3/2018
Banner MD Anderson Cancer Center
mi
from
Gilbert, AZ
Click here to add this to my saved trials
Treatment of Symptomatic BPH Patients Undergoing Anticoagulant Therapy Using the PlasmaButton Vaporization Electrode
Treatment of Symptomatic BPH Patients Undergoing Anticoagulant Therapy Using the PlasmaButton Vaporization Electrode - An Observational Study
Status: Enrolling
Updated:  4/3/2018
Loma Linda University Medical Center Urology Department
mi
from
Loma Linda, CA
Treatment of Symptomatic BPH Patients Undergoing Anticoagulant Therapy Using the PlasmaButton Vaporization Electrode
Treatment of Symptomatic BPH Patients Undergoing Anticoagulant Therapy Using the PlasmaButton Vaporization Electrode - An Observational Study
Status: Enrolling
Updated: 4/3/2018
Loma Linda University Medical Center Urology Department
mi
from
Loma Linda, CA
Click here to add this to my saved trials
Treatment of Symptomatic BPH Patients Undergoing Anticoagulant Therapy Using the PlasmaButton Vaporization Electrode
Treatment of Symptomatic BPH Patients Undergoing Anticoagulant Therapy Using the PlasmaButton Vaporization Electrode - An Observational Study
Status: Enrolling
Updated:  4/3/2018
VA Greater Los Angeles Healthcare System
mi
from
Los Angeles, CA
Treatment of Symptomatic BPH Patients Undergoing Anticoagulant Therapy Using the PlasmaButton Vaporization Electrode
Treatment of Symptomatic BPH Patients Undergoing Anticoagulant Therapy Using the PlasmaButton Vaporization Electrode - An Observational Study
Status: Enrolling
Updated: 4/3/2018
VA Greater Los Angeles Healthcare System
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Acute Myeloid Leukemia
A Phase 2 Study of MEK 1/2 Inhibitor Trametinib in Combination With AKT Inhibitor GSK2141795 in Acute Myeloid Leukemia (AML) With RAS Mutations
Status: Enrolling
Updated:  4/4/2018
University of Chicago Comprehensive Cancer Center
mi
from
Chicago, IL
Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Acute Myeloid Leukemia
A Phase 2 Study of MEK 1/2 Inhibitor Trametinib in Combination With AKT Inhibitor GSK2141795 in Acute Myeloid Leukemia (AML) With RAS Mutations
Status: Enrolling
Updated: 4/4/2018
University of Chicago Comprehensive Cancer Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Acute Myeloid Leukemia
A Phase 2 Study of MEK 1/2 Inhibitor Trametinib in Combination With AKT Inhibitor GSK2141795 in Acute Myeloid Leukemia (AML) With RAS Mutations
Status: Enrolling
Updated:  4/4/2018
University of Maryland Greenebaum Cancer Center
mi
from
Baltimore, MD
Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Acute Myeloid Leukemia
A Phase 2 Study of MEK 1/2 Inhibitor Trametinib in Combination With AKT Inhibitor GSK2141795 in Acute Myeloid Leukemia (AML) With RAS Mutations
Status: Enrolling
Updated: 4/4/2018
University of Maryland Greenebaum Cancer Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Acute Myeloid Leukemia
A Phase 2 Study of MEK 1/2 Inhibitor Trametinib in Combination With AKT Inhibitor GSK2141795 in Acute Myeloid Leukemia (AML) With RAS Mutations
Status: Enrolling
Updated:  4/4/2018
M D Anderson Cancer Center
mi
from
Houston, TX
Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Acute Myeloid Leukemia
A Phase 2 Study of MEK 1/2 Inhibitor Trametinib in Combination With AKT Inhibitor GSK2141795 in Acute Myeloid Leukemia (AML) With RAS Mutations
Status: Enrolling
Updated: 4/4/2018
M D Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Reference Range Study for the Quantra Analyzer With the Quantra Surgical Cartridge
Reference Range Study for the Quantra Analyzer With the Quantra Surgical Cartridge
Status: Enrolling
Updated:  4/4/2018
University of Maryland Medical Center
mi
from
Baltimore, MD
Reference Range Study for the Quantra Analyzer With the Quantra Surgical Cartridge
Reference Range Study for the Quantra Analyzer With the Quantra Surgical Cartridge
Status: Enrolling
Updated: 4/4/2018
University of Maryland Medical Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
Reference Range Study for the Quantra Analyzer With the Quantra Surgical Cartridge
Reference Range Study for the Quantra Analyzer With the Quantra Surgical Cartridge
Status: Enrolling
Updated:  4/4/2018
Creedmoor Centre Endocrinology
mi
from
Raleigh, NC
Reference Range Study for the Quantra Analyzer With the Quantra Surgical Cartridge
Reference Range Study for the Quantra Analyzer With the Quantra Surgical Cartridge
Status: Enrolling
Updated: 4/4/2018
Creedmoor Centre Endocrinology
mi
from
Raleigh, NC
Click here to add this to my saved trials
Reference Range Study for the Quantra Analyzer With the Quantra Surgical Cartridge
Reference Range Study for the Quantra Analyzer With the Quantra Surgical Cartridge
Status: Enrolling
Updated:  4/4/2018
Medical University of South Carolina
mi
from
Charleston, SC
Reference Range Study for the Quantra Analyzer With the Quantra Surgical Cartridge
Reference Range Study for the Quantra Analyzer With the Quantra Surgical Cartridge
Status: Enrolling
Updated: 4/4/2018
Medical University of South Carolina
mi
from
Charleston, SC
Click here to add this to my saved trials
Hemofiltration in Burns: RESCUE (Randomized Controlled Evaluation of Hemofiltration in Adult Burn Patients With Septic Shock and Acute Renal Failure)
The American Burn Association's Randomized Controlled Evaluation of Hemofiltration in Adult Burn Patients With Septic Shock and Acute Renal Failure
Status: Enrolling
Updated:  4/5/2018
Arizona Burn Center
mi
from
Phoenix, AZ
Hemofiltration in Burns: RESCUE (Randomized Controlled Evaluation of Hemofiltration in Adult Burn Patients With Septic Shock and Acute Renal Failure)
The American Burn Association's Randomized Controlled Evaluation of Hemofiltration in Adult Burn Patients With Septic Shock and Acute Renal Failure
Status: Enrolling
Updated: 4/5/2018
Arizona Burn Center
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Hemofiltration in Burns: RESCUE (Randomized Controlled Evaluation of Hemofiltration in Adult Burn Patients With Septic Shock and Acute Renal Failure)
The American Burn Association's Randomized Controlled Evaluation of Hemofiltration in Adult Burn Patients With Septic Shock and Acute Renal Failure
Status: Enrolling
Updated:  4/5/2018
Tampa General Hospital
mi
from
Tampa, FL
Hemofiltration in Burns: RESCUE (Randomized Controlled Evaluation of Hemofiltration in Adult Burn Patients With Septic Shock and Acute Renal Failure)
The American Burn Association's Randomized Controlled Evaluation of Hemofiltration in Adult Burn Patients With Septic Shock and Acute Renal Failure
Status: Enrolling
Updated: 4/5/2018
Tampa General Hospital
mi
from
Tampa, FL
Click here to add this to my saved trials
Hemofiltration in Burns: RESCUE (Randomized Controlled Evaluation of Hemofiltration in Adult Burn Patients With Septic Shock and Acute Renal Failure)
The American Burn Association's Randomized Controlled Evaluation of Hemofiltration in Adult Burn Patients With Septic Shock and Acute Renal Failure
Status: Enrolling
Updated:  4/5/2018
Doctors Hospital-Joseph M Still Burn Center
mi
from
Augusta, GA
Hemofiltration in Burns: RESCUE (Randomized Controlled Evaluation of Hemofiltration in Adult Burn Patients With Septic Shock and Acute Renal Failure)
The American Burn Association's Randomized Controlled Evaluation of Hemofiltration in Adult Burn Patients With Septic Shock and Acute Renal Failure
Status: Enrolling
Updated: 4/5/2018
Doctors Hospital-Joseph M Still Burn Center
mi
from
Augusta, GA
Click here to add this to my saved trials
Hemofiltration in Burns: RESCUE (Randomized Controlled Evaluation of Hemofiltration in Adult Burn Patients With Septic Shock and Acute Renal Failure)
The American Burn Association's Randomized Controlled Evaluation of Hemofiltration in Adult Burn Patients With Septic Shock and Acute Renal Failure
Status: Enrolling
Updated:  4/5/2018
Loyola University Medical Center
mi
from
Maywood, IL
Hemofiltration in Burns: RESCUE (Randomized Controlled Evaluation of Hemofiltration in Adult Burn Patients With Septic Shock and Acute Renal Failure)
The American Burn Association's Randomized Controlled Evaluation of Hemofiltration in Adult Burn Patients With Septic Shock and Acute Renal Failure
Status: Enrolling
Updated: 4/5/2018
Loyola University Medical Center
mi
from
Maywood, IL
Click here to add this to my saved trials
Hemofiltration in Burns: RESCUE (Randomized Controlled Evaluation of Hemofiltration in Adult Burn Patients With Septic Shock and Acute Renal Failure)
The American Burn Association's Randomized Controlled Evaluation of Hemofiltration in Adult Burn Patients With Septic Shock and Acute Renal Failure
Status: Enrolling
Updated:  4/5/2018
University of Kansas Hospital
mi
from
Kansas City, KA
Hemofiltration in Burns: RESCUE (Randomized Controlled Evaluation of Hemofiltration in Adult Burn Patients With Septic Shock and Acute Renal Failure)
The American Burn Association's Randomized Controlled Evaluation of Hemofiltration in Adult Burn Patients With Septic Shock and Acute Renal Failure
Status: Enrolling
Updated: 4/5/2018
University of Kansas Hospital
mi
from
Kansas City, KA
Click here to add this to my saved trials
Hemofiltration in Burns: RESCUE (Randomized Controlled Evaluation of Hemofiltration in Adult Burn Patients With Septic Shock and Acute Renal Failure)
The American Burn Association's Randomized Controlled Evaluation of Hemofiltration in Adult Burn Patients With Septic Shock and Acute Renal Failure
Status: Enrolling
Updated:  4/5/2018
The Regional Med Ctr, Memphis
mi
from
Memphis, TN
Hemofiltration in Burns: RESCUE (Randomized Controlled Evaluation of Hemofiltration in Adult Burn Patients With Septic Shock and Acute Renal Failure)
The American Burn Association's Randomized Controlled Evaluation of Hemofiltration in Adult Burn Patients With Septic Shock and Acute Renal Failure
Status: Enrolling
Updated: 4/5/2018
The Regional Med Ctr, Memphis
mi
from
Memphis, TN
Click here to add this to my saved trials
Hemofiltration in Burns: RESCUE (Randomized Controlled Evaluation of Hemofiltration in Adult Burn Patients With Septic Shock and Acute Renal Failure)
The American Burn Association's Randomized Controlled Evaluation of Hemofiltration in Adult Burn Patients With Septic Shock and Acute Renal Failure
Status: Enrolling
Updated:  4/5/2018
University of Texas Southwestern Medical Center-Burn Center Parkland Health
mi
from
Dallas, TX
Hemofiltration in Burns: RESCUE (Randomized Controlled Evaluation of Hemofiltration in Adult Burn Patients With Septic Shock and Acute Renal Failure)
The American Burn Association's Randomized Controlled Evaluation of Hemofiltration in Adult Burn Patients With Septic Shock and Acute Renal Failure
Status: Enrolling
Updated: 4/5/2018
University of Texas Southwestern Medical Center-Burn Center Parkland Health
mi
from
Dallas, TX
Click here to add this to my saved trials
Hemofiltration in Burns: RESCUE (Randomized Controlled Evaluation of Hemofiltration in Adult Burn Patients With Septic Shock and Acute Renal Failure)
The American Burn Association's Randomized Controlled Evaluation of Hemofiltration in Adult Burn Patients With Septic Shock and Acute Renal Failure
Status: Enrolling
Updated:  4/5/2018
U.S. Army Institute of Surgical Research
mi
from
Fort Sam Houston, TX
Hemofiltration in Burns: RESCUE (Randomized Controlled Evaluation of Hemofiltration in Adult Burn Patients With Septic Shock and Acute Renal Failure)
The American Burn Association's Randomized Controlled Evaluation of Hemofiltration in Adult Burn Patients With Septic Shock and Acute Renal Failure
Status: Enrolling
Updated: 4/5/2018
U.S. Army Institute of Surgical Research
mi
from
Fort Sam Houston, TX
Click here to add this to my saved trials
Hemofiltration in Burns: RESCUE (Randomized Controlled Evaluation of Hemofiltration in Adult Burn Patients With Septic Shock and Acute Renal Failure)
The American Burn Association's Randomized Controlled Evaluation of Hemofiltration in Adult Burn Patients With Septic Shock and Acute Renal Failure
Status: Enrolling
Updated:  4/5/2018
The Burn Center at Washington Hospital Center
mi
from
Washington,
Hemofiltration in Burns: RESCUE (Randomized Controlled Evaluation of Hemofiltration in Adult Burn Patients With Septic Shock and Acute Renal Failure)
The American Burn Association's Randomized Controlled Evaluation of Hemofiltration in Adult Burn Patients With Septic Shock and Acute Renal Failure
Status: Enrolling
Updated: 4/5/2018
The Burn Center at Washington Hospital Center
mi
from
Washington,
Click here to add this to my saved trials
Montelukast to Treat Bronchiolitis Obliterans
Multi-Institutional Prospective Phase II Study of Montelukast for the Treatment of Bronchiolitis Obliterans Following Allogeneic or Autologous Stem Cell Transplantation in Children and Adults
Status: Enrolling
Updated:  4/6/2018
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Montelukast to Treat Bronchiolitis Obliterans
Multi-Institutional Prospective Phase II Study of Montelukast for the Treatment of Bronchiolitis Obliterans Following Allogeneic or Autologous Stem Cell Transplantation in Children and Adults
Status: Enrolling
Updated: 4/6/2018
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Ixazomib Plus Pomalidomide and Dexamethasone in Treating Patients With Relapsed or Relapsed/Refractory Multiple Myeloma
Phase I/II Trial of MLN9708 Plus Pomalidomide and Dexamethasone for Relapsed or Relapsed Refractory Multiple Myeloma
Status: Enrolling
Updated:  4/6/2018
Mayo Clinic
mi
from
Scottsdale, AZ
Ixazomib Plus Pomalidomide and Dexamethasone in Treating Patients With Relapsed or Relapsed/Refractory Multiple Myeloma
Phase I/II Trial of MLN9708 Plus Pomalidomide and Dexamethasone for Relapsed or Relapsed Refractory Multiple Myeloma
Status: Enrolling
Updated: 4/6/2018
Mayo Clinic
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Ixazomib Plus Pomalidomide and Dexamethasone in Treating Patients With Relapsed or Relapsed/Refractory Multiple Myeloma
Phase I/II Trial of MLN9708 Plus Pomalidomide and Dexamethasone for Relapsed or Relapsed Refractory Multiple Myeloma
Status: Enrolling
Updated:  4/6/2018
City of Hope Medical Center
mi
from
Duarte, CA
Ixazomib Plus Pomalidomide and Dexamethasone in Treating Patients With Relapsed or Relapsed/Refractory Multiple Myeloma
Phase I/II Trial of MLN9708 Plus Pomalidomide and Dexamethasone for Relapsed or Relapsed Refractory Multiple Myeloma
Status: Enrolling
Updated: 4/6/2018
City of Hope Medical Center
mi
from
Duarte, CA
Click here to add this to my saved trials
Ixazomib Plus Pomalidomide and Dexamethasone in Treating Patients With Relapsed or Relapsed/Refractory Multiple Myeloma
Phase I/II Trial of MLN9708 Plus Pomalidomide and Dexamethasone for Relapsed or Relapsed Refractory Multiple Myeloma
Status: Enrolling
Updated:  4/6/2018
Emory University/Winship Cancer Institute
mi
from
Atlanta, GA
Ixazomib Plus Pomalidomide and Dexamethasone in Treating Patients With Relapsed or Relapsed/Refractory Multiple Myeloma
Phase I/II Trial of MLN9708 Plus Pomalidomide and Dexamethasone for Relapsed or Relapsed Refractory Multiple Myeloma
Status: Enrolling
Updated: 4/6/2018
Emory University/Winship Cancer Institute
mi
from
Atlanta, GA
Click here to add this to my saved trials
Ixazomib Plus Pomalidomide and Dexamethasone in Treating Patients With Relapsed or Relapsed/Refractory Multiple Myeloma
Phase I/II Trial of MLN9708 Plus Pomalidomide and Dexamethasone for Relapsed or Relapsed Refractory Multiple Myeloma
Status: Enrolling
Updated:  4/6/2018
The Mayo Clinic
mi
from
Rochester, MN
Ixazomib Plus Pomalidomide and Dexamethasone in Treating Patients With Relapsed or Relapsed/Refractory Multiple Myeloma
Phase I/II Trial of MLN9708 Plus Pomalidomide and Dexamethasone for Relapsed or Relapsed Refractory Multiple Myeloma
Status: Enrolling
Updated: 4/6/2018
The Mayo Clinic
mi
from
Rochester, MN
Click here to add this to my saved trials
Ixazomib Plus Pomalidomide and Dexamethasone in Treating Patients With Relapsed or Relapsed/Refractory Multiple Myeloma
Phase I/II Trial of MLN9708 Plus Pomalidomide and Dexamethasone for Relapsed or Relapsed Refractory Multiple Myeloma
Status: Enrolling
Updated:  4/6/2018
Sarah Cannon Research Institute (SCRI)
mi
from
Nashville, TN
Ixazomib Plus Pomalidomide and Dexamethasone in Treating Patients With Relapsed or Relapsed/Refractory Multiple Myeloma
Phase I/II Trial of MLN9708 Plus Pomalidomide and Dexamethasone for Relapsed or Relapsed Refractory Multiple Myeloma
Status: Enrolling
Updated: 4/6/2018
Sarah Cannon Research Institute (SCRI)
mi
from
Nashville, TN
Click here to add this to my saved trials
Tocilizumab for Treatment of Steroid Refractory Acute Graft-versus-Host Disease
Phase I-II Study Using Tocilizumab for Treatment of Steroid Refractory Acute Graft-versus-Host Disease
Status: Enrolling
Updated:  4/9/2018
Froedtert Hospital/ Medical College of Wisconsin - Clinical Cancer Center
mi
from
Milwaukee, WI
Tocilizumab for Treatment of Steroid Refractory Acute Graft-versus-Host Disease
Phase I-II Study Using Tocilizumab for Treatment of Steroid Refractory Acute Graft-versus-Host Disease
Status: Enrolling
Updated: 4/9/2018
Froedtert Hospital/ Medical College of Wisconsin - Clinical Cancer Center
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Study to Determine the Maximum Tolerated Dose for the Combination of Pomalidomide, Bortezomib and Low-Dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
A Phase 1, Multicenter, Open Label, Dose-escalation Study to Determine the Maximum Tolerated Dose for the Combination of Pomalidomide (POM), Bortezomib (BTZ) and Low-Dose Dexamethasone (LDDEX) in Subjects With Relapsed or Refractory Multiple Myeloma (MM)
Status: Enrolling
Updated:  4/9/2018
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Study to Determine the Maximum Tolerated Dose for the Combination of Pomalidomide, Bortezomib and Low-Dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
A Phase 1, Multicenter, Open Label, Dose-escalation Study to Determine the Maximum Tolerated Dose for the Combination of Pomalidomide (POM), Bortezomib (BTZ) and Low-Dose Dexamethasone (LDDEX) in Subjects With Relapsed or Refractory Multiple Myeloma (MM)
Status: Enrolling
Updated: 4/9/2018
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
Study to Determine the Maximum Tolerated Dose for the Combination of Pomalidomide, Bortezomib and Low-Dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
A Phase 1, Multicenter, Open Label, Dose-escalation Study to Determine the Maximum Tolerated Dose for the Combination of Pomalidomide (POM), Bortezomib (BTZ) and Low-Dose Dexamethasone (LDDEX) in Subjects With Relapsed or Refractory Multiple Myeloma (MM)
Status: Enrolling
Updated:  4/9/2018
Dana-Farber Cancer Institute
mi
from
Boston, MA
Study to Determine the Maximum Tolerated Dose for the Combination of Pomalidomide, Bortezomib and Low-Dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
A Phase 1, Multicenter, Open Label, Dose-escalation Study to Determine the Maximum Tolerated Dose for the Combination of Pomalidomide (POM), Bortezomib (BTZ) and Low-Dose Dexamethasone (LDDEX) in Subjects With Relapsed or Refractory Multiple Myeloma (MM)
Status: Enrolling
Updated: 4/9/2018
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Study to Determine the Maximum Tolerated Dose for the Combination of Pomalidomide, Bortezomib and Low-Dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
A Phase 1, Multicenter, Open Label, Dose-escalation Study to Determine the Maximum Tolerated Dose for the Combination of Pomalidomide (POM), Bortezomib (BTZ) and Low-Dose Dexamethasone (LDDEX) in Subjects With Relapsed or Refractory Multiple Myeloma (MM)
Status: Enrolling
Updated:  4/9/2018
Massachusetts General Hospital
mi
from
Boston, MA
Study to Determine the Maximum Tolerated Dose for the Combination of Pomalidomide, Bortezomib and Low-Dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
A Phase 1, Multicenter, Open Label, Dose-escalation Study to Determine the Maximum Tolerated Dose for the Combination of Pomalidomide (POM), Bortezomib (BTZ) and Low-Dose Dexamethasone (LDDEX) in Subjects With Relapsed or Refractory Multiple Myeloma (MM)
Status: Enrolling
Updated: 4/9/2018
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Study to Determine the Maximum Tolerated Dose for the Combination of Pomalidomide, Bortezomib and Low-Dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
A Phase 1, Multicenter, Open Label, Dose-escalation Study to Determine the Maximum Tolerated Dose for the Combination of Pomalidomide (POM), Bortezomib (BTZ) and Low-Dose Dexamethasone (LDDEX) in Subjects With Relapsed or Refractory Multiple Myeloma (MM)
Status: Enrolling
Updated:  4/9/2018
Winship Cancer Institute at Emory University
mi
from
Atlanta, GA
Study to Determine the Maximum Tolerated Dose for the Combination of Pomalidomide, Bortezomib and Low-Dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
A Phase 1, Multicenter, Open Label, Dose-escalation Study to Determine the Maximum Tolerated Dose for the Combination of Pomalidomide (POM), Bortezomib (BTZ) and Low-Dose Dexamethasone (LDDEX) in Subjects With Relapsed or Refractory Multiple Myeloma (MM)
Status: Enrolling
Updated: 4/9/2018
Winship Cancer Institute at Emory University
mi
from
Atlanta, GA
Click here to add this to my saved trials
Study to Determine the Maximum Tolerated Dose for the Combination of Pomalidomide, Bortezomib and Low-Dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
A Phase 1, Multicenter, Open Label, Dose-escalation Study to Determine the Maximum Tolerated Dose for the Combination of Pomalidomide (POM), Bortezomib (BTZ) and Low-Dose Dexamethasone (LDDEX) in Subjects With Relapsed or Refractory Multiple Myeloma (MM)
Status: Enrolling
Updated:  4/9/2018
Hackensack University Medical Center
mi
from
Hackensack, NJ
Study to Determine the Maximum Tolerated Dose for the Combination of Pomalidomide, Bortezomib and Low-Dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
A Phase 1, Multicenter, Open Label, Dose-escalation Study to Determine the Maximum Tolerated Dose for the Combination of Pomalidomide (POM), Bortezomib (BTZ) and Low-Dose Dexamethasone (LDDEX) in Subjects With Relapsed or Refractory Multiple Myeloma (MM)
Status: Enrolling
Updated: 4/9/2018
Hackensack University Medical Center
mi
from
Hackensack, NJ
Click here to add this to my saved trials